Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Open accessThe DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.
Abstract
Mood disorders are common, chronic, recurrent mental illnesses that affect the lives of millions of individuals worldwide. To date, the monoaminergic systems (serotonergic, noradrenergic and dopaminergic) in the brain have received the greatest attention in neurobiological studies of mood disorders, and most therapeutics target these systems. However, there is growing evidence that the glutamatergic system is central to the neurobiology and treatment of these disorders. Here, we review data supporting the involvement of the glutamatergic system in mood-disorder pathophysiology as well as the efficacy of glutamatergic agents in mood disorders. We also discuss exciting new prospects for the development of improved therapeutics for these devastating disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This could lead to astrocyte/microglia imbalance, glutamatergic overproduction and excitotoxic neuronal damage (Sanacora et al., 2008) with impact on synapse functionality.”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, increased glutamate levels has been associated with mechanisms involved in stress and depression, such as neuro-inflammatory process, decreased levels of neurotrophic factors, diminished neurogenesis, and neuroplasticity impairment [116,117].”
From P2X7 Receptor Signaling in Stress and Depression (2019) · cites this paper as [117]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, rapidly acting antidepressants were discovered in the glutamatergic system (Berman et al., 2000;Sanacora et al., 2008).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Several classes of antidepressants as well as SSRIs are known to exert action on the glutamate system by influencing NMDA or AMPA receptor transcription (Sanacora et al., 2008).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Glia also play an important role in regulating the synthesis and reuptake of glutamate and thereby influence synaptic function and morphology16,17.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“Although most patients with mood disorders receive some benefit from available treatment”
BackgroundTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationEvidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043 · cited 1×
“, and is approved for the treatment of moderate to severe Alzheimer's disease, in which it has been shown to enhance cognition and minimize clinical deterioration in patients with Alzheimer's disease, vascular dementia or mixed dementi”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Epilepsy and Exacerbation of Brain Injury in Mice Lacking the Glutamate Transporter GLT-1
Tanaka, K., Watase, K., Manabe, T., Yamada, K., Watanabe, M., Takahashi, K., Iwama, H., Nishikawa, T., Ichihara, N., Kikuchi, T., et al. (1997) · Science · doi:10.1126/science.276.5319.1699 · Cited by 1,752
Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways
Hardingham, G. E., Fukunaga, Y., & Bading, H. (2002) · Nature Neuroscience · doi:10.1038/nn835 · Cited by 1,686
Glial reduction in the subgenual prefrontal cortex in mood disorders
Öngür, D., Drevets, W. C., & Price, J. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13290 · Cited by 1,525
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518
Rajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
Astrocyte Control of Synaptic Transmission and Neurovascular Coupling
Haydon, P. G., & Carmignoto, G. (2006) · Physiological Reviews · doi:10.1152/physrev.00049.2005 · Cited by 1,323
The role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244
The cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182
Self-citationDrevets, W. C. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00203-8 · Cited by 1,146
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Self-citationRessler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1136 · Cited by 1,063
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells
Rajkowska, G. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00950-1 · Cited by 822
Functional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785
Cotter, D., Mackay, D., Landau, S., Kerwin, R., & Everall, I. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.6.545 · Cited by 766
Metabolism and role of glutamate in mammalian brain
Erecińska, M., & Silver, I. A. (1990) · Progress in Neurobiology · doi:10.1016/0301-0082(90)90013-7 · Cited by 682
Bowden, C. L. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.481 · Cited by 678
Choudary, P. V., Molnar, M., Evans, S. J., Tomita, H., Li, J. Z., Vawter, M. P., Myers, R. M., Bunney, W. E., Akil, H., Watson, S. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507901102 · Cited by 652
Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity.
Rothstein, J. D., Jin, L., Dykes-Hoberg, M., & Kuncl, R. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6591 · Cited by 623
Gliogenesis and Glial Pathology in Depression
Rajkowska, G., & Miguel-Hidalgo, J. (2007) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152707780619326 · Cited by 610
Increased Levels of Glutamate in Brains from Patients with Mood Disorders
Hashimoto, K., Sawa, A., & Iyo, M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.017 · Cited by 609
The Origin and Neuronal Function of In Vivo Nonsynaptic Glutamate
Baker, D. A., Xi, Z.-X., Shen, H., Swanson, C. J., & Kalivas, P. W. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-20-09134.2002 · Cited by 584
Rajkowska, G., Halaris, A., & Selemon, L. D. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01080-0 · Cited by 570
Low glial numbers in the amygdala in major depressive disorder
Bowley, M. P., Drevets, W. C., Öngür, D., & Price, J. L. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01404-x · Cited by 503
Effects of D-Cycloserine on Extinction: Translation From Preclinical to Clinical Work
Davis, M., Ressler, K., Rothbaum, B. O., & Richardson, R. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.084 · Cited by 498
Quantitative studies on some antagonists of N‐methyl D‐aspartate in slices of rat cerebral cortex
Harrison, N. L., & Simmonds, M. A. (1985) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1985.tb12922.x · Cited by 485
Peng, J., Kim, M. J., Cheng, D., Duong, D. M., Gygi, S. P., & Sheng, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400103200 · Cited by 473
The McLean-Harvard First-Episode Mania Study: Prediction of Recovery and First Recurrence
Tohen, M., Zarate, C. A., Hennen, J., Khalsa, H.-M. K., Strakowski, S. M., Gebre-Medhin, P., Salvatore, P., & Baldessarini, R. J. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.12.2099 · Cited by 471
Self-citationVaroqui, H., Schäfer, M. K.-H., Zhu, H., Weihe, E., & Erickson, J. D. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-01-00142.2002 · Cited by 451
Glutamate in CNS disorders as a target for drug development: an update
Parsons, C. G., Danysz, W., & Quack, G. (1998) · Drug News & Perspectives · doi:10.1358/dnp.1998.11.9.863689 · Cited by 438
Excitatory amino acid transmission: Neurology and neurobiology, volume 24
Hicks, T. P., Lodge, D., McClennan, H., Hardy, J. A., & Cowburn, R. F. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80857-8 · Cited by 432
Nonaka, S., Hough, C. J., & Chuang, D.-M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2642 · Cited by 427
N-Methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease
FAN, M., & RAYMOND, L. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.11.003 · Cited by 413
Moran, M. M., McFarland, K., Melendez, R. I., Kalivas, P. W., & Seamans, J. K. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1007-05.2005 · Cited by 411
Woo, T.-U. W., Walsh, J. P., & Benes, F. M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.7.649 · Cited by 411
Interaction of the N-Ethylmaleimide–Sensitive Factor with AMPA Receptors
Song, I., Kamboj, S., Xia, J., Dong, H., Liao, D., & Huganir, R. L. (1998) · Neuron · doi:10.1016/s0896-6273(00)80548-6 · Cited by 398
A Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387
Self-citationD-Cycloserine Augmented Exposure Therapy for Obsessive-Compulsive Disorder
Kushner, M. G., Kim, S. W., Donahue, C., Thuras, P., Adson, D., Kotlyar, M., McCabe, J., Peterson, J., & Foa, E. B. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.020 · Cited by 384
Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes
Hamidi, M., Drevets, W. C., & Price, J. L. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.11.006 · Cited by 369 · cited 1×
“Although some evidence suggests that glial abnormalities are predominantly due to reduced numbers of oligodendrocyte”
BackgroundNeuropharmacology of AMPA and kainate receptors
Bleakman, D., & Lodge, D. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00139-7 · Cited by 363
Skolnick, P., Layer, R., Popik, P., Nowak, G., Paul, I., & Trullas, R. (1996) · Pharmacopsychiatry · doi:10.1055/s-2007-979537 · Cited by 344
Neuroplasticity and cellular resilience in mood disorders
Manji, H. K., Moore, G. J., Rajkowska, G., & Chen, G. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000811 · Cited by 340
Self-citationMiguel-Hidalgo, J. J., Baucom, C., Dilley, G., Overholser, J. C., Meltzer, H. Y., Stockmeier, C. A., & Rajkowska, G. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00999-9 · Cited by 336
Correlation between plasma levels of glutamate, alanine and serine with severity of depression
Mitani, H., Shirayama, Y., Yamada, T., Maeda, K., Ashby, C. R., & Kawahara, R. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.03.036 · Cited by 332
Guastella, A. J., Richardson, R., Lovibond, P. F., Rapee, R. M., Gaston, J. E., Mitchell, P., & Dadds, M. R. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.11.011 · Cited by 326 · cited 1×
“, recent clinical studies have shown that lower doses of D -cycloserine are effective in enhancing the efficacy of exposure-based therapies for anxiety disorders; no significant effect was seen when the higher dose of 500 mg per day was use”
ResultAn Open-Label Trial of Riluzole in Patients With Treatment-Resistant Major Depression
Zarate, C. A., Payne, J. L., Quiroz, J., Sporn, J., Denicoff, K. K., Luckenbaugh, D., Charney, D. S., & Manji, H. K. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.171 · Cited by 324
Self-citationIvanov, A., Pellegrino, C., Rama, S., Dumalska, I., Salyha, Y., Ben‐Ari, Y., & Medina, I. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.105510 · Cited by 319
Hashimoto, R., Hough, C., Nakazawa, T., Yamamoto, T., & Chuang, D. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00728.x · Cited by 310
Lauterborn, J. C., Lynch, G., Vanderklish, P., Arai, A., & Gall, C. M. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-01-00008.2000 · Cited by 290
Beyond Monoamines: Glutamatergic Function in Mood Disorders
Kugaya, A., & Sanacora, G. (2005) · CNS Spectrums · doi:10.1017/s1092852900010403 · Cited by 290
Self-citationLocalization of VGLUT3, the vesicular glutamate transporter type 3, in the rat brain
Herzog, E., Gilchrist, J., Gras, C., Muzerelle, A., Ravassard, P., Giros, B., Gaspar, P., & El Mestikawy, S. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2003.10.039 · Cited by 283
Nowak, G., Ordway, G. A., & Paul, I. A. (1995) · Brain Research · doi:10.1016/0006-8993(95)00057-w · Cited by 262
Disability and its treatment in bipolar disorder patients
Huxley, N., & Baldessarini, R. J. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00430.x · Cited by 262
Zarate, C. A., Quiroz, J. A., Singh, J. B., Denicoff, K. D., De Jesus, G., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.023 · Cited by 257
Self-citationNierenberg, A. A., Ostacher, M. J., Calabrese, J. R., Ketter, T. A., Marangell, L. B., Miklowitz, D. J., Miyahara, S., Bauer, M. S., Thase, M. E., Wisniewski, S. R., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.210 · Cited by 257
Plasma and platelet excitatory amino acids in psychiatric disorders
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.11.1731 · Cited by 243
mGluR5 stimulates gliotransmission in the nucleus accumbens
D'Ascenzo, M., Fellin, T., Terunuma, M., Revilla-Sanchez, R., Meaney, D. F., Auberson, Y. P., Moss, S. J., & Haydon, P. G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609408104 · Cited by 243
Glutamatergic systems in Alzheimer's disease
Francis, P. T. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.934 · Cited by 242
Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments.
Paul, I. A., Nowak, G., Layer, R. T., Popik, P., & Skolnick, P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38715-x · Cited by 241
Increased cerebrospinal fluid glutamine levels in depressed patients
Levine, J., Panchalingam, K., Rapoport, A., Gershon, S., McClure, R. J., & Pettegrew, J. W. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00284-x · Cited by 240
How can drug discovery for psychiatric disorders be improved?
Agid, Y., Buzsáki, G., Diamond, D. M., Frackowiak, R., Giedd, J., Girault, J.-A., Grace, A., Lambert, J. J., Manji, H., Mayberg, H., et al. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2217 · Cited by 240
Self-citationBonanno, G., Giambelli, R., Raiteri, L., Tiraboschi, E., Zappettini, S., Musazzi, L., Raiteri, M., Racagni, G., & Popoli, M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5033-04.2005 · Cited by 234
Krystal, J. (1999) · Harvard Review of Psychiatry · doi:10.1093/hrp/7.3.125 · Cited by 232
Self-citationThe Role of Glutamate in Anxiety and Related Disorders
Cortese, B. M., & Phan, K. L. (2005) · CNS Spectrums · doi:10.1017/s1092852900010427 · Cited by 232
Mauri, M. C., Ferrara, A., Boscati, L., Bravin, S., Zamberlan, F., Alecci, M., & Invernizzi, G. (1998) · Neuropsychobiology · doi:10.1159/000026491 · Cited by 231
Svenningsson, P., Tzavara, E. T., Witkin, J. M., Fienberg, A. A., Nomikos, G. G., & Greengard, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052712799 · Cited by 230
Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses
Law, A. J., & Deakin, J. F. W. (2001) · Neuroreport · doi:10.1097/00001756-200109170-00043 · Cited by 227
Antidepressant-like actions of an AMPA receptor potentiator (LY392098)
Li, X., Tizzano, J. P., Griffey, K., Clay, M., Lindstrom, T., & Skolnick, P. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(00)00194-5 · Cited by 225
Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis
Pitt, D., Nagelmeier, I. E., Wilson, H. C., & Raine, C. S. (2003) · Neurology · doi:10.1212/01.wnl.0000090564.88719.37 · Cited by 222
Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs
Palucha, A., & Pilc, A. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.04.007 · Cited by 220
Riluzole Enhances Glutamate Uptake in Rat Astrocyte Cultures
Frizzo, M. E. D. S., Dall'Onder, L. P., Dalcin, K. B., & Souza, D. O. (2004) · Cellular and Molecular Neurobiology · doi:10.1023/b:cemn.0000012717.37839.07 · Cited by 212
Green, S. M., Rothrock, S. G., Harris, T., Hopkins, G. A., Garrett, W., & Sherwin, T. (1998) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.1998.tb02773.x · Cited by 210
Debono, M.-W., Le Guern, J., Canton, T., Doble, A., & Pradier, L. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90147-a · Cited by 210
Is Cocaine Desire Reduced by N -Acetylcysteine?
LaRowe, S. D., Myrick, H., Hedden, S., Mardikian, P., Saladin, M., McRae, A., Brady, K., Kalivas, P. W., & Malcolm, R. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1115 · Cited by 210
Du, J., Suzuki, K., Wei, Y., Wang, Y., Blumenthal, R., Chen, Z., Falke, C., Zarate, C. A., & Manji, H. K. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301178 · Cited by 208
Self-citationFunctional impairment in the remission phase of bipolar disorder
Fagiolini, A., Kupfer, D. J., Masalehdan, A., Scott, J. A., Houck, P. R., & Frank, E. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00207.x · Cited by 206
Sanacora, G., Kendell, S. F., Levin, Y., Simen, A. A., Fenton, L. R., Coric, V., & Krystal, J. H. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.037 · Cited by 199
Self-citationLafleur, D. L., Pittenger, C., Kelmendi, B., Gardner, T., Wasylink, S., Malison, R. T., Sanacora, G., Krystal, J. H., & Coric, V. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0246-6 · Cited by 199
Self-citationNowak, G., Trullas, R., Layer, R. T., Skolnick, P., & Paul, I. A. (1993) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38235-2 · Cited by 196
Altamura, C., Maes, M., Dai, J., & Meltzer, H. Y. (1995) · European Neuropsychopharmacology · doi:10.1016/0924-977x(95)00033-l · Cited by 193
McCullumsmith, R. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00370-0 · Cited by 191
Increased serum glutamate in depressed patients
Kim, J. S., Schmid-Burgk, W., Claus, D., & Kornhuber, H. H. (1982) · Archiv f�r Psychiatrie und Nervenkrankheiten · doi:10.1007/bf00345492 · Cited by 189
A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2006) · Archives of Neurology · doi:10.1001/archneur.63.1.49 · Cited by 181
Efficacy and Tolerability of an mGlu2/3 Agonist in the Treatment of Generalized Anxiety Disorder
Dunayevich, E., Erickson, J., Levine, L., Landbloom, R., Schoepp, D. D., & Tollefson, G. D. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301531 · Cited by 179
Maes, M., Verkerk, R., Vandoolaeghe, E., Lin, A., & Scharpé, S. (1998) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1998.tb10004.x · Cited by 179
Webster, M. J., Knable, M. B., Johnston-Wilson, N., Nagata, K., Inagaki, M., & Yolken, R. H. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2001.0646 · Cited by 179
Neural circuitry and neuroplasticity in mood disorders: Insights for novel therapeutic targets
Carlson, P. J., Singh, J. B., Zarate, C. A., Drevets, W. C., & Manji, H. K. (2006) · NeuroRx · doi:10.1016/j.nurx.2005.12.009 · Cited by 177
Self-citationClinton, S. M., & Meador-Woodruff, J. H. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300451 · Cited by 176
Physiological Roles and Therapeutic Potential of Metabotropic Glutamate Receptors
Conn, P. J. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.002 · Cited by 174
Black, M. D. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2065-6 · Cited by 174
Boyer, P., Skolnick, P., & Fossom, L. H. (1998) · Journal of Molecular Neuroscience · doi:10.1007/bf02761776 · Cited by 171
Toro, C. T., & Deakin, J. F. W. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.003 · Cited by 169
Low Cerebrospinal Fluid Glutamate and Glycine in Refractory Affective Disorder
Frye, M. A., Tsai, G. E., Huggins, T., Coyle, J. T., & Post, R. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.01.024 · Cited by 166
ZARATE, C. A., DU, J., QUIROZ, J., GRAY, N. A., DENICOFF, K. D., SINGH, J., CHARNEY, D. S., & MANJI, H. K. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.017 · Cited by 164
Self-citationAntidepressant-Like Effects of Ceftriaxone in Male C57BL/6J Mice
Mineur, Y. S., Picciotto, M. R., & Sanacora, G. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.037 · Cited by 163
Self-citationDecreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder
McCullumsmith, R. E., Kristiansen, L. V., Beneyto, M., Scarr, E., Dean, B., & Meador‐Woodruff, J. H. (2006) · Brain Research · doi:10.1016/j.brainres.2006.09.011 · Cited by 162
Du, J., Gray, N. A., Falke, C. A., Chen, W., Yuan, P., Szabo, S. T., Einat, H., & Manji, H. K. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1258-04.2004 · Cited by 157
Self-citationL�scher, W. (1993) · Neurochemical Research · doi:10.1007/bf00967253 · Cited by 156
Orrego, F., & Villanueva, S. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90355-j · Cited by 156
Meador‐Woodruff, J. H., Hogg, A. J., & Smith, R. E. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00523-8 · Cited by 154
Martucci, L., Wong, A. H. C., Luca, V. D., Likhodi, O., Wong, G. W. H., King, N. A., & Kennedy, J. L. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.02.001 · Cited by 154
Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model
Knapp, R. J., Goldenberg, R., Shuck, C., Cecil, A., Watkins, J. B., Miller, C., Crites, G. J., & Malatyńska, E. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01338-9 · Cited by 153
Nudmamud‐Thanoi, S., & Reynolds, G. P. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.09.035 · Cited by 150
In vivo1H‐[13C]‐NMR spectroscopy of cerebral metabolism
de Graaf, R. A., Mason, G. F., Patel, A. B., Behar, K. L., & Rothman, D. L. (2003) · NMR in Biomedicine · doi:10.1002/nbm.847 · Cited by 146
Mizuta, I., Ohta, M., Ohta, K., Nishimura, M., Mizuta, E., & Kuno, S. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02098-5 · Cited by 145
Bai, F., Bergeron, M., & Nelson, D. L. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00104-7 · Cited by 144
Metabotropic Glutamate Receptors in the Control of Mood Disorders
Witkin, J. M., Marek, G. J., Johnson, B., & Schoepp, D. D. (2007) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152707780363302 · Cited by 140
Zeise, M. L., Kasparow, S., & Zieglgänsberger, W. (1991) · Brain Research · doi:10.1016/0006-8993(91)90078-a · Cited by 139
Chronic Elevation of Brain-Derived Neurotrophic Factor by Ampakines
Lauterborn, J. C., Truong, G. S., Baudry, M., Bi, X., LYNCH, G. S., & Gall, C. M. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.053694 · Cited by 138
Karasawa, J.-I., Shimazaki, T., Kawashima, N., & Chaki, S. (2005) · Brain Research · doi:10.1016/j.brainres.2005.02.032 · Cited by 137
Chapter 11 AMPA receptors: Molecular and functional diversity
Borges, K., & Dingledine, R. J. (1998) · Progress in brain research · doi:10.1016/s0079-6123(08)60436-7 · Cited by 130
Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder
Scarr, E., Pavey, G., Sundram, S., Mackinnon, A. J., & Dean, B. (2003) · Bipolar Disorders · doi:10.1034/j.1399-5618.2003.00024.x · Cited by 130
CYLOSERINE AS AN ANTIDEPRESSANT AGENT
CRANE, G. E. (1959) · American Journal of Psychiatry · doi:10.1176/ajp.115.11.1025 · Cited by 127
Beneyto, M., & Meador‐Woodruff, J. H. (2006) · Synapse · doi:10.1002/syn.20329 · Cited by 124
Basselin, M., Chang, L., Bell, J. M., & Rapoport, S. I. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300920 · Cited by 121
Childhood adversity and vulnerability to mood and anxiety disorders
Young, E. A., Abelson, J. L., Curtis, G. C., & Nesse, R. M. (1997) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1997)5:2<66::aid-da2>3.0.co;2-3 · Cited by 118
The effects of aging on spinal neurochemistry in the rat
Ko, M. L., King, M. A., Gordon, T. L., & Crisp, T. (1997) · Brain Research Bulletin · doi:10.1016/s0361-9230(96)00216-x · Cited by 117
Psychiatric safety of ketamine in psychopharmacology research
Perry, E. B., Cramer, J. A., Cho, H.-S., Petrakis, I. L., Karper, L. P., Genovese, A., O’Donnell, E., Krystal, J. H., D’Souza, D. C., & Yale Ketamine Study Group (2007) · Psychopharmacology · doi:10.1007/s00213-007-0706-2 · Cited by 117
Self-citationKristiansen, L. V., & Meador‐Woodruff, J. H. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.06.012 · Cited by 116
An open-label, flexible-dose study of memantine in major depressive disorder
Ferguson, J. M., & Shingleton, R. N. (2007) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3180314ae7 · Cited by 113 · cited 1×
“It is possible, however, that antidepressant effects might have occurred with much higher doses of memantine, as suggested by another recent open-label flexible dosing study of memantine in subjects with MD”
ResultOpen channel block of NMDA receptor responses evoked by tricyclic antidepressants
Sernagor, E., Kuhn, D. M., Vyklický, L., & Mayer, M. L. (1989) · Neuron · doi:10.1016/0896-6273(89)90306-1 · Cited by 110
Michael-Titus, A. T., Bains, S., Jeetle, J. K., & Whelpton, R. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00390-0 · Cited by 109
The Role of Hippocampal GluR1 and GluR2 Receptors in Manic-Like Behavior
Du, J., Creson, T. K., Wu, L.-J., Ren, M., Gray, N. A., Falke, C., Wei, Y., Wang, Y., Blumenthal, R., Machado-Vieira, R., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3080-07.2008 · Cited by 107
Self-citationMundo, E., Tharmalingham, S., Neves-Pereira, M., Dalton, E. J., Macciardi, F. M., Parikh, S. V., Bolonna, A. A., Kerwin, R. W., Arranz, M. J., MAKOFF, A. J., et al. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001218 · Cited by 105
Toro, C. T., Hallak, J. E. C., Dunham, J. S., & Deakin, J. F. W. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.05.067 · Cited by 105
Zarate, C. A., MD, Quiroz, J., MD, Payne, J., MD, Manji, A. H. K., & MD (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4204 · Cited by 104
Self-citationBarbon, A., Popoli, M., Via, L. L., Moraschi, S., Vallini, I., Tardito, D., Tiraboschi, E., Musazzi, L., Giambelli, R., Gennarelli, M., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.10.018 · Cited by 104
Selective cortical VGLUT1 increase as a marker for antidepressant activity
Moutsimilli, L., Farley, S., Dumas, S., Mestikawy, S. E., Giros, B., & Tzavara, E. T. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.06.017 · Cited by 101
A Brief Overview of the Clinical Pharmacology of “Club Drugs”
Britt, G. C., & McCance‐Katz, E. F. (2005) · Substance Use & Misuse · doi:10.1081/ja-200066730 · Cited by 99
Paul, I. A., Layer, R. T., Skolnick, P., & Nowak, G. (1993) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(93)90199-j · Cited by 97
Dixon, J. F., Los, G. V., & Hokin, L. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8358 · Cited by 97
Francis, P. T., Poynton, A., Lowe, S. L., Najlerahim, A., Bridges, P. K., Bartlett, J. R., PROCTER, A. W., Bruton, C. J., & Bowen, D. M. (1989) · Brain Research · doi:10.1016/0006-8993(89)90600-8 · Cited by 96
Controlled trial of d-cycloserine adjuvant therapy for treatment-resistant major depressive disorder
Heresco-Levy, U., Javitt, D. C., Gelfin, Y., Gorelik, E., Bar, M., Blanaru, M., & Kremer, I. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.03.004 · Cited by 89 · cited 1×
“A subsequent double-blind, placebo-controlled, 6-week crossover study involving 22 patients with treatment-resistant MDD found the addition of D -cycloserine at 250 mg per day to other antidepressants to be ineffectiv”
BackgroundUp‐regulation of hippocampal glutamate transport during chronic treatment with sodium valproate
Hassel, B., Iversen, E. G., Gjerstad, L., & Taubøll, E. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00349.x · Cited by 82
Effects of riluzole on electrically evoked neurotransmitter release
Jehle, T., Bauer, J., Blauth, E., Hummel, A., Darstein, M., Freiman, T. M., & Feuerstein, T. J. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703424 · Cited by 82
Pittaluga, A., Raiteri, L., Longordo, F., Luccini, E., Barbiero, V. S., Racagni, G., Popoli, M., & Raiteri, M. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.04.006 · Cited by 77
The schizophrenia ketamine challenge study debate
Carpenter, W. T. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00194-8 · Cited by 73
Glia mechanisms in mood regulation: a novel model of mood disorders
Lee, Y., Gaskins, D. L., Anand, A., & Shekhar, A. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0652-4 · Cited by 73
Ma, J., & Zhang, G. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00784-5 · Cited by 68
Steppuhn, K. G., & Turski, L. (1993) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38256-x · Cited by 66
Inhibitors of the Glutamate Vesicular Transporter (VGLUT)
Thompson, C., Davis, E., Carrigan, C., Cox, H., Bridges, R., & Gerdes, J. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867054637635 · Cited by 64
Ueda, Y., & Willmore, L. J. (2000) · Experimental Brain Research · doi:10.1007/s002210000443 · Cited by 62
Tordera, R. M., Pei, Q., & Sharp, T. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03192.x · Cited by 61
Nowak, G., Legutko, B., Skolnick, P., & Popik, P. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01589-6 · Cited by 61
Wong, M., Smith, M. A., Licinio, J., Doi, S. Q., Weiss, S. R. B., Post, R. M., & Gold, P. W. (1993) · Epilepsy Research · doi:10.1016/0920-1211(93)90046-a · Cited by 61
Behavioral and Neuroendocrine Effects of the Partial NMDA Agonist D-cycloserine in Healthy Subjects
van Berckel, B. N. M., Lipsch, C., Timp, S., Wied, C. G.-D., Wynne, H., van Ree, J. M., & Kahn, R. S. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00196-0 · Cited by 61
Biology of schizophrenia and affective disease
Alarcón, R. D. (1997) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1997)5:2<112::aid-da9>3.0.co;2-h · Cited by 59
Valproate modifies spontaneous excitation and inhibition at cortical synapses in vitro
Cunningham, M. O., Woodhall, G. L., & Jones, R. S. G. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00270-3 · Cited by 57
Du, J., GRAY, N. A., Falke, C., Yuan, P., Szabo, S. T., & Manji, H. K. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.031 · Cited by 56
Self-citationThe psychotropic effects of cycloserine: A new use for an antibiotic
Crane, G. E. (1961) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(61)80007-2 · Cited by 55
Biology of schizophrenia and affective disease
Watson, S. J., & Meeting, M. D. (1996) · American Psychiatric Press eBooks · Cited by 54
Treating Neurodegenerative Diseases with Antibiotics
Miller, T. M., & Cleveland, D. W. (2005) · Science · doi:10.1126/science.1109027 · Cited by 52
The Effects of Anticonvulsant Drugs on NMDA-EPSP, AMPA-EPSP, and GABA-IPSP in the Rat Hippocampus
Ko, G. Y.-P., Brown-Croyts, L. M., & Teyler, T. J. (1997) · Brain Research Bulletin · doi:10.1016/s0361-9230(96)00268-7 · Cited by 50
Hokin, L. E., Dixon, J. F., & Los, G. V. (1996) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(95)00021-6 · Cited by 49
Repeated ECS induces GluR1 mRNA but not NMDAR1A-G mRNA in the rat hippocampus
Naylor, P., Stewart, C. A., Wright, S. R., Pearson, R. C. A., & Reid, I. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(95)00264-s · Cited by 48
Ahmad, S., Fowler, L. J., & Whitton, P. S. (2005) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-004-1008-4 · Cited by 48
Teng, C. T., & Demétrio, F. N. (2006) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462006000300020 · Cited by 47
Payne, J. L., Quiroz, J. A., Zarate, C. A., & Manji, H. K. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01676-1 · Cited by 46 · cited 1×
“These observations suggest that although monoaminergic neurotransmitter systems have an important role in the pathophysiology and treatment of mood disorders, other systems that regulate synaptic and neural plasticity are more central to the neurobiology and treatment of these disorder”
BackgroundSelf-citationLiverton, N. J., Bednar, R. A., Bednar, B., Butcher, J. W., Claiborne, C. F., Claremon, D. A., Cunningham, M., DiLella, A. G., Gaul, S. L., Libby, B. E., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm060983w · Cited by 44
Borza, I., Bozó, É., BARTA‐SZALAI, G., Kiss, C., Tárkányi, G., Demeter, Á., Gáti, T., Háda, V., Kolok, S., Gere, A., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm060420k · Cited by 43
The partial NMDA agonist D -cycloserine stimulates LH secretion in healthy volunteers
van Berckel, B. N. M., Lipsch, C., Wied, C. C. G., Wynne, H. J. A., Blankenstein, M. A., van Ree, J. M., & Kahn, R. S. (1998) · Psychopharmacology · doi:10.1007/s002130050662 · Cited by 40
Martínez-Turrillas, R., Río, J. D., & Frechilla, D. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.12.078 · Cited by 39
Kang, T., Kim, D.-S., Kwak, S., Kim, J.-E., Kim, D. W., Kang, J. H., Won, M., Kwon, O.-S., & Choi, S. Y. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.08.007 · Cited by 36
Excitatory Amino Acid Transmission in Health and Disease
Balázs, R., Bridges, R. J., Cotman, C. W., & Cotman, C. A. (2005) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195150025.001.0001 · Cited by 35
Wang, M., Yang, Y., Dong, Z., Cao, J., & Xu, L. (2006) · NeuroReport · doi:10.1097/01.wnr.0000227994.07799.6c · Cited by 35
Künig, G., Niedermeyer, B., Deckert, J., Gsell, W., Ransmayr, G. N., & Riederer, P. F. (1998) · Epilepsy Research · doi:10.1016/s0920-1211(98)00022-9 · Cited by 24
Suetake-Koga, S., Shimazaki, T., Takamori, K., Chaki, S., Kanuma, K., Sekiguchi, Y., Suzuki, T., Kikuchi, T., Matsui, Y., & Honda, T. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.04.018 · Cited by 23
Inhibition of N-methyl-l-aspartate activated ion current by desmethylimipramine
White, G., Lovinger, D. M., Peoples, R. W., & Weight, F. F. (1990) · Brain Research · doi:10.1016/0006-8993(90)90381-k · Cited by 21
Stoll, L., Seguin, S. P., & Gentile, L. N. (2006) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2006.12.004 · Cited by 20
Dixon, J. F., & Hokin, L. E. (1994) · Biochemical Journal · doi:10.1042/bj3040251 · Cited by 18
Searching for Rational Anti–N-methyl-D-aspartate Treatment for Depression
Tsai, G. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.9.1099 · Cited by 18
Antidepressants and gene expression profiling: how to SNARE novel drug targets
Lesch, K., & Schmitt-Böhrer, A. G. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500150 · Cited by 18
Lithium modulates desensitization of the glutamate receptor subtype GluR3 in Xenopus oocytes
Karkanias, N. B., & Papke, R. L. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00878-2 · Cited by 14
The N-Methyl-D-Aspartate Receptor Complex
Williams, M. J., Loo, P. A., Murphy, D. E., Braunwalder, A. F., Jarvis, M. F., & Sills, M. A. (1988) · Journal of Receptor Research · doi:10.3109/10799898809048987 · Cited by 14
Amyotrophic Lateral Sclerosis — A New Role for Old Drugs
Brown, R. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmcibr050274 · Cited by 13
[The N-methyl-D-aspartate receptor complex. Various sites of regulation and clinical consequences].
Turski, L. (1990) · PubMed · Cited by 11
Searching for Rational Anti–N-methyl-D-aspartate Treatment forDepression—Reply
Zarate, C. A., Charney, D. S., & Manji, H. K. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.9.1100 · Cited by 6
Self-citation
Research works printed but not linked: 1
- Preskorn, S. et al. A placebo-controlled trial of the NR2B subunit specific NMDA antagonist CP-101,606 plus paroxetine for treatment resistant depression (TRD). Annual Conference of the American Psychological Association (San Francisco, California) 154 (2007).
Cited by
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
Self-citationSynaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651
The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission
Popoli, M., Yan, Z., McEwen, B. S., & Sanacora, G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3138 · Cited by 1,393
Self-citationMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Metadata
- Authors
- Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K.
- Affiliations
- Yale University (US)
- National Institutes of Health (US)
- Corresponding author
- Manji, Husseini K.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2008-05
- Volume
- 7
- Issue
- 5
- Pages
- 426-437
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC2715836
- OpenAlex
- W2074907255
- Cited by
- 894
- References
- 186
- Citations by year
- 2026: 17 · 2025: 29 · 2024: 33 · 2023: 44 · 2022: 36 · 2021: 44 · 2020: 56 · 2019: 43 · 2018: 40 · 2017: 50 · 2016: 63 · 2015: 70 · 2014: 59 · 2013: 56 · 2012: 68
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (K02MH076222, Z01MH002828, Z01MH002857)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- glutamatergic system, mood disorders, antidepressants, neuroplasticity, glutamatergic agents, monoaminergic systems, rapid-acting antidepressants, drug development
- MeSH terms
- Animals, Glutamates, Humans, Psychotropic Drugs, Excitatory Amino Acid Antagonists, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.